Advertisement

Topics

"A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment" Drugs and Medication Database

22:02 EST 23rd February 2019 | BioPortfolio

Here are the most relevant "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment" Drugs and Medications that we have found in our database.

More Information about "A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment" on BioPortfolio

We have published hundreds of A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment news stories on BioPortfolio along with dozens of A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment Clinical Trials and PubMed Articles about A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment Companies in our database. You can also find out about relevant A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment Drugs and Medications on this site too.

Showing "Study E7080 Alone Combination With Everolimus Subjects With" Drugs and Medications, all 23

Probably Relevant

Oxygen [mon healthcare]

Oxygen

Oxygen [fairmont home equipment & supply]

Oxygen

Oxygen [fielden gas products, inc.]

Oxygen

Oxygen [kalispell medical equipment]

NA

Oxygen [superior oxygen & medical equipment]

Oxygen

Oxygen [johnson drug company, inc]

OXYGEN COMPRESSED USP

Oxygen [smith's drugs fo forest city, inc. dba smith drugs]

NA

Possibly Relevant

Fluoxetine [med-health pharma, llc]

These highlights do not include all the information needed to use fluoxetine safely and effectively. See full prescribing information for fluoxetine capsules. Fluoxetine Capsules, USP for Oral Use Initial U.S. Approval: 1987

Oxygen [dubois medical supply company, inc]

OXYGEN 1234

Oxygen [support medical systems, inc.]

Oxygen

Oxygen [rezk medical supply]

NA

Cabometyx [exelixis, inc.]

These highlights do not include all the information needed to use CABOMETYX safely and effectively. See full prescribing information for CABOMETYX.CABOMETYX (cabozantinib) tablets, for oral use Initial U.S. Approval: 2012

Lenvima [eisai inc.]

These highlights do not include all the information needed to use LENVIMA safely and effectively. See full prescribing information for LENVIMA .     LENVIMA ( lenvatinib ) capsules , for oral use Initial U.S. Approval: 2015

Vinorelbine [sagent pharmaceuticals]

These highlights do not include all the information needed to use VINORELBINE INJECTION safely and effectively. See full prescribing information for VINORELBINE INJECTION. VINORELBINE injection, for intravenous useInitial U.S. Approval: 1994

Farydak [novartis pharmaceuticals corporation]

These highlights do not include all the information needed to use FARYDAK safely and effectively. See full prescribing information for FARYDAK. FARYDAK (panobinostat) capsules, for oral use Initial U.S. Approval: 2015

Repaglinide [rising health, llc]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS. REPAGLINIDE tablets, for oral use Initial U.S. Approval: 1997

Repaglinide [aurobindo pharma limited]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively.  See full prescribing information for REPAGLINIDE TABLETS. REPAGLINIDE tablets, for oral use Initial U.S. Approval: 1997

Docetaxel [amneal biosciences llc]

These highlights do not include all the information needed to use DOCETAXEL INJECTION safely and effectively. See full prescribing information for DOCETAXEL INJECTION.   DOCETAXEL injection, for intravenous use Initial U.S. Approval: 1996

Docetaxel [x-gen pharmaceuticals, inc.]

These highlights do not include all the information needed to use DOCETAXEL INJECTION USP (Injection Concentrate) safely and effectively. See full prescribing information for DOCETAXEL INJECTION USP (Injection Concentrate). DOCETAXEL Injection (Injection

Rebetol [merck sharp & dohme corp.]

These highlights do not include all the information needed to use REBETOL safely and effectively. See full prescribing information for REBETOL.REBETOL (ribavirin USP) capsules, for oral use REBETOL (ribavirin USP) oral solutionInitial U.S. Approval: 1998

Trilyte [alaven pharmaceutical llc]

TriLyte with flavor packs

Repaglinide [sun pharmaceutical industries, inc.]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively. See full prescribing information for REPAGLINIDE TABLETS.REPAGLINIDE tablets, for oral useInitial U.S. Approval: 1997

Repaglinide [american health packaging]

These highlights do not include all the information needed to use REPAGLINIDE TABLETS safely and effectively. See full prescribing information for REPAGLINIDE TABLETS. REPAGLINIDE tablets, for oral use Initial U.S. Approval: 1997



Advertisement
Quick Search
Advertisement
Advertisement